Serum tumor markers in bile duct cancer - a review

被引：31

作者：

Grunnet, M. ^{[1
]}

Mau-Sorensen, M. ^{[1
]}

机构：

[1] Danish Natl Hosp, Rigshosp, Dept Oncol, Copenhagen, Denmark

来源：

BIOMARKERS | 2014年 / 19卷 / 06期

关键词：

Bile duct cancer; biomarker; cholangiocarcinoma; diagnosis; prognosis; serum; TOTAL SIALIC-ACID; CARCINOEMBRYONIC ANTIGEN CEA; INTRAHEPATIC CHOLANGIOCARCINOMA; PANCREATIC-CANCER; DETECTING CHOLANGIOCARCINOMA; CLINICAL-SIGNIFICANCE; MUC5AC MUCIN; PROGNOSTIC-FACTOR; NATURAL-HISTORY; GENE-EXPRESSION;

D O I：

10.3109/1354750X.2014.923048

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Context: Bile duct cancer (BDC) is a disease with a very grave prognosis, often diagnosed too late. Objective: The aim of this review is to evaluate available literature on tumor markers in serum from patients with BDC. Methods: Using the search words "serum markers'', "bile duct cancer'', "cholangiocarcinoma'', "biomarker'' and "tumor marker'', a search was carried out. Results: Seventy-five studies were included in the review. Conclusion: CA19-9 is by far the most studied and most promising diagnostic and/or prognostic marker in BDC. But also the different mucins are interesting as new markers of BDC in serum.

引用

页码：437 / 443

页数：7

共 101 条

[31]

Heinemann V, 1999, ANTICANCER RES, V19, P2433

[32] CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial [J].

Hess, Viviane ;

Glimelius, Bengt ;

Grawe, Philipp ;

Dietrich, Daniel ;

Bodoky, Gyoergy ;

Ruhstaller, Thomas ;

Bajetta, Emilio ;

Saletti, Piercarlo ;

Figer, Arie ;

Scheithauer, Werner ;

Herrmann, Richard .

LANCET ONCOLOGY, 2008, 9 (02) :132-138

[33] Outcomes after resection of cholangiocellular carcinoma [J].

Huang, JL ;

Biehl, TR ;

Lee, FT ;

Zimmer, PW ;

Ryan, JA .

AMERICAN JOURNAL OF SURGERY, 2004, 187 (05) :612-617

[34] A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis [J].

Hultcrantz, R ;

Olsson, R ;

Danielsson, B ;

Järnerot, C ;

Lööf, L ;

Ryden, BO ;

Wahren, B ;

Broomé, U .

JOURNAL OF HEPATOLOGY, 1999, 30 (04) :669-673

[35] Expression of matrix metalloproteinose 7 is an unfavorable postoperative prognostic factor in cholongiocarcinoma of the perihilar, hilar, and extrahepatic bile ducts [J].

Itatsu, Keita ;

Zen, Yoh ;

Yamaguchi, Junpei ;

Ohira, Shusaku ;

Ishikawa, Akira ;

Ikeda, Hiroko ;

Sato, Yasunori ;

Harada, Kenichi ;

Sasaki, Motoko ;

Sasaki, Masatoshi ;

Sakamoto, Hiroya ;

Nagino, Masato ;

Nimura, Yuji ;

Ohta, Tetsuo ;

Nakanuma, Yasuni .

HUMAN PATHOLOGY, 2008, 39 (05) :710-719

[36] TUMOR MARKERS AS A DIAGNOSTIC KEY FOR HILAR CHOLANGIOCARCINOMA [J].

Juntermanns, B. ;

Radunz, S. ;

Heuer, M. ;

Hertel, S. ;

Reis, H. ;

Neuhaus, J. P. ;

Vernadakis, S. ;

Trarbach, T. ;

Paul, A. ;

Kaiser, G. M. .

EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2010, 15 (08) :357-361

[37] ASSESSMENT OF SERUM AND BILE LEVELS OF CA19-9 AND CA125 IN CHOLANGITIS AND BILE-DUCT CARCINOMA [J].

KER, CG ;

CHEN, JS ;

LEE, KT ;

SHEEN, PC ;

WU, CC .

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1991, 6 (05) :505-508

[38] Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update [J].

Khan, Shahid A. ;

Davidson, Brian R. ;

Goldin, Robert D. ;

Heaton, Nigel ;

Karani, John ;

Pereira, Stephen P. ;

Rosenberg, William M. C. ;

Tait, Paul ;

Taylor-Robinson, Simon D. ;

Thillainayagam, Andrew V. ;

Thomas, Howard C. ;

Wasan, Harpreet .

GUT, 2012, 61 (12) :1657-1669

[39]

Kim HJ, 1999, AM J GASTROENTEROL, V94, P1941

[40]

Kongtawelert P, 2003, WORLD J GASTROENTERO, V9, P2178

← 1 2 3 4 5 6 7 8 9 10 →